Genprex (NASDAQ:GNPX) Releases Quarterly Earnings Results

Genprex (NASDAQ:GNPX) announced its quarterly earnings results on Friday. The company reported ($9.40) earnings per share (EPS) for the quarter, Zacks reports.

Genprex Price Performance

NASDAQ GNPX traded down $0.55 during trading hours on Friday, hitting $4.32. The company’s stock had a trading volume of 90,681 shares, compared to its average volume of 230,247. Genprex has a 12 month low of $4.00 and a 12 month high of $1,210.00. The company’s 50 day simple moving average is $9.49 and its two-hundred day simple moving average is $25.26. The company has a market cap of $2.18 million, a P/E ratio of -0.01 and a beta of -0.88.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Genprex in a research note on Friday, July 17th. Wall Street Zen upgraded shares of Genprex from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Hedge Funds Weigh In On Genprex

A hedge fund recently raised its position in Genprex stock. Susquehanna International Group LLP increased its stake in shares of Genprex (NASDAQ:GNPX) by 11.7% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 340,056 shares of the company’s stock after purchasing an additional 35,661 shares during the period. Susquehanna International Group LLP owned approximately 27.20% of Genprex worth $58,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 14.05% of the company’s stock.

About Genprex

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.